- Home
- ACAD vs PAX Comparison
ACAD vs PAX Comparison
Compare ACAD & PAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- PAX
- Stock Information
- Founded
- ACAD 1993
- PAX 1988
- Country
- ACAD United States
- PAX Cayman Islands
- Employees
- ACAD N/A
- PAX N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- PAX Investment Managers
- Sector
- ACAD Health Care
- PAX Finance
- Exchange
- ACAD Nasdaq
- PAX Nasdaq
- Market Cap
- ACAD 2.5B
- PAX 2.0B
- IPO Year
- ACAD 2004
- PAX 2021
- Fundamental
- Price
- ACAD $21.57
- PAX $12.74
- Analyst Decision
- ACAD Buy
- PAX Strong Buy
- Analyst Count
- ACAD 14
- PAX 1
- Target Price
- ACAD $27.08
- PAX $14.00
- AVG Volume (30 Days)
- ACAD 3.0M
- PAX 682.3K
- Earning Date
- ACAD 05-07-2025
- PAX 05-02-2025
- Dividend Yield
- ACAD N/A
- PAX 4.71%
- EPS Growth
- ACAD N/A
- PAX N/A
- EPS
- ACAD 1.37
- PAX 0.45
- Revenue
- ACAD $996,283,000.00
- PAX $389,900,000.00
- Revenue This Year
- ACAD $13.49
- PAX $6.61
- Revenue Next Year
- ACAD $10.58
- PAX N/A
- P/E Ratio
- ACAD $15.76
- PAX $28.13
- Revenue Growth
- ACAD 22.42
- PAX 22.70
- 52 Week Low
- ACAD $13.40
- PAX $9.43
- 52 Week High
- ACAD $25.23
- PAX $13.34
- Technical
- Relative Strength Index (RSI)
- ACAD 68.70
- PAX 65.67
- Support Level
- ACAD $21.95
- PAX $12.76
- Resistance Level
- ACAD $22.62
- PAX $13.15
- Average True Range (ATR)
- ACAD 1.21
- PAX 0.30
- MACD
- ACAD 0.23
- PAX 0.01
- Stochastic Oscillator
- ACAD 56.27
- PAX 62.33
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About PAX Patria Investments Limited
Patria Investments Ltd is a private markets investment firm. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns.